Literature DB >> 20848841

[Studies about the level of CD4+ CD25+ regulatory T cells and relation between expression of Foxp3 and CD127 in peripheral blood of chronic HBV infection].

Min Deng1, Ming-Hui Li, Shun-Ai Liu, Feng Liu, Yan Sang, Shu-Jing Song, Shu-Feng Zang, Xiao-Ping Guan, Xie Yao, Xiao-Ping Wu, Jun Cheng, Dao-Zhen Xu.   

Abstract

OBJECTIVE: To investigate the level of CD4+ CD25+ Foxp3+ regulatory T cells and observe relation between expression of Foxp3 and CD127 in peripheral blood of chronic HBV infection.
METHODS: CD4+ CD25+ Foxp3+ and CD4+ CD25+ CD127low Treg in peripheral blood from 34 patients of immune tolerance stage, 26 patients of immune clearance stage and 31 patients of non-active status were quantitatively analyzed by flow cytometry.
RESULTS: Immune tolerance group presented a higher fraction of CD4+ CD25+ Foxp3+ and CD4+ CD25+ CD127low Treg than non-active group in chronic HBV infection (Z = -2.693, P = 0.007 and t = 3.251, P = 0.002), and HBV positive group also presented a higher fraction than non-active group (t = 2.266, P = 0.026 and t = 3.208, P = 0.002), But ALT normal group is similar to ALT abnormal group (P > 0.05). In this study, the relation between expression of CD127low and Foxp3+ from CD4+ CD25+ regulatory T cells was observed, and CD4+ CD25+ CD127low Treg presented a higher fraction than CD4+ CD25+ Foxp3+ Treg.
CONCLUSION: Peripheral Treg in HBV active replication group is higher than HBV negative group of chronic HBV infection. Expression of CD127low is consistent with Foxp3+ in CD4+ CD25+ regulatory T cells, but the former is significantly higher than the latter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848841

Source DB:  PubMed          Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi        ISSN: 1003-9279


  1 in total

1.  CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.

Authors:  Zong-Sheng Tang; You-Hua Hao; E-Juan Zhang; Chun-Li Xu; Yun Zhou; Xin Zheng; Dong-Liang Yang
Journal:  Mol Med Rep       Date:  2016-06-13       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.